Immunotherapy with chemoradiation for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests adding medicines that block TGF-beta and PD-L1 to standard chemoradiation for esophageal squamous cell cancer that can’t be removed with surgery. It aims to improve control of the cancer where it sits, while keeping treatment safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell cancer of the esophagus or the area where the esophagus meets the stomach
- Your tumor is not removable by surgery (not fully curable with surgery), and scans show no distant spread (except certain lymph node-only cases)
- If you had prior treatment or surgery, the cancer has come back only in the nearby area—not spread to distant organs
- You are at least 18, and your overall health is good enough for treatment (ECOG 0–2)
- Blood tests, liver/kidney function, and clotting tests must be within required limits
- You cannot have certain prior treatments, lung conditions, autoimmune disease on immune-suppressing meds, or other listed exclusions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving chemotherapy and radiation before surgery, followed by immunotherapy, can improve outcomes for people with a specific type of esophageal cancer that can be surgically removed.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial tests a treatment for locally advanced esophageal cancer. You'll receive chemoradiation (chemo plus radiation) followed by a maintenance drug (a PD-1 inhibitor) to help prevent the cancer from coming back.
This trial tests a new combination of short-course radiation, an immunotherapy drug (tislelizumab), and chemotherapy before surgery for esophageal cancer. It aims to shrink tumors and improve surgical outcomes.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
This trial tests a new immunotherapy drug (camrelizumab) combined with standard chemotherapy and radiation to treat advanced esophageal cancer while avoiding surgery if possible. The goal is to shrink the tumor and help you keep your esophagus working.
Hear when a new Carcinoma, Squamous Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.